Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Investigate the Safety and Preliminary Efficacy of EBV CAR-T Cells in the Treatment of Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma

NCT05654077 is registered in ClinicalTrials.gov with The Affiliated Hospital of Xuzhou Medical University as lead sponsor.

NCT NCT05654077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05654077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Investigate the Safety and Preliminary Efficacy of EBV CAR-T Cells in the Treatment of Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
January 18, 2022
Completion date
December 30, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma